GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

This Ontario listing comes two months after Canada's Drug Agency (formerly CADTH) issued a reimbursement recommendation for VRAYLAR, and just days after AbbVie successfully reached an agreement ...

The global body contouring treatments market growth forecasted to transform from USD 1.46 billion in 2024 to USD 2.58 billion ...

For more information about AbbVie, please visit us at www.abbvie.ca. Follow AbbVie Canada on Twitter, on Instagram or find us on LinkedIn. 1 Mental Health Commission of Canada. The Aspiring Workforce: ...

The CEO of Hungarian pharmaceutical company Richter reiterated 2024 guidance on Tuesday after it reported higher ...

AbbVie is currently addressing serious health ... 30% from Western Europe, Canada, Japan and Australia and 40% from the fastest-growing economies, including India, China, Russia and Brazil.

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

Welcome to the AbbVie third quarter 2024 earnings conference call. [Operator instructions] I would now like to introduce Ms.

The third-quarter earnings season was at its peak this week for large drugmakers, with several companies — Eli Lilly LLY, ...

AbbVie's Vice President and General Manager in Canada. "It is humbling to see such widespread support for DLBCL patients to quickly access EPKINLY – demonstrating how urgently needed medicines ...

AbbVie tries to fast-track new cancer drug for ... Vyalev, also known as Produodopa, is already approved in 35 countries, including Canada, Japan and those in the European Union.